Although the Affordable Care Act (ACA) legislation was passed in 2010, the most significant changes are slated for a 2014 effective date. Companies are re-evaluating the role of the employer in providing healthcare benefits and analyzing when to pay and how to play, the role of public and private exchanges, approaches to bending the cost curve, and managing the compliance burdens created by ACA.
During this Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast, PwC tax and consulting professionals present an overview of our recent Emerging Markets Operations Study and provide a discussion about opportunities and implications to your business from a tax perspective.
The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.
Merger and acquisition deal value in the pharmaceutical and life sciences sector increased in the first quarter of 2013 relative to the first quarter of 2012. The pharmaceutical segment recorded the largest gains in deal value during the quarter on the strength of several large transactions.
PwC recently convened several roundtables of employers in New York, Chicago, and Atlanta to discuss health coverage at this pivotal moment. This thought leadership article highlights the conversations and results of the related survey.
Watch this webcast featuring Jay Crowley from FDA and Jeffrey Secunda from AdvaMed as featured speakers. During this webcast, Jay and Jeffrey provide their perspectives on the future of UDI in the medical device industry.
The next installment in PwC's Healthcare, Higher Education and Not-for-Profit quarterly webcast series provides updates on the various standard setting activities that have occurred since our January webcast. As always, the focus is on how those activities will affect not-for-profit organizations, with an emphasis on healthcare and higher education institutions.
Watch this PwC webcast for a discussion regarding the recently issued proposed guidance affecting every tax-exempt hospital organization. This webcast also reviews hospital facility’s community health needs assessment (CHNA) requirements and reporting obligations and features a broad range of PwC specialists.
China recently introduced its 12th Five-Year Plan, which reinforces the government's commitment to easing ownership requirements. This 10Minutes discusses opportunities that private and foreign providers, payers, and investors can adopt to build a presence in China's growing healthcare market.
Healthcare companies have been gathering feedback from patients for years. Now, the accessibility of that feedback is influencing people’s healthcare decision making. Reporting requirements on ratings and reviews are prompting insurers and providers to look more comprehensively at the consumer experience.
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that medical device manufacturers will need to begin accounting for this tax for all sales, other than tax free sales, beginning January 1, 2013 and will need to consider the impact of this tax on their 2013 results.
The new HIPAA changes will have immediate consequences. It is important for organizations to understand the financial and operational implications and develop a well thought out strategy to remain in compliance and support the new health information uses, health IT and channels.
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that the new tax law extends research & development tax credit and provides guidance on accounting for the retroactive reinstatement of the R&D tax credit.
The Center for Medicare & Medicaid Services (CMS) released the highly anticipated Final Rule implementing the physician payment sunshine provisions on Section 6002 of the Affordable Care Act. PwC provides a summary of the key provisions of the Final Rule as well as a facilitated discussion about the impact of the provisions on the industry’s efforts to develop, implement and maintain the processes and systems necessary to comply with the law.
HR Innovation offers advanced thinking about the challenges that should be uppermost on the minds and agendas of organizations and their Human Resources (HR) leaders. In this issue of HR Innovation, we focus on HR Transaction Effectiveness, and delve into what it takes to effectively navigate the maze of critical talent-based decisions that can support deal success, shorten the time to close, and boost value.
On August 22, 2012 the SEC issued a final rule on conflict minerals pursuant to Dodd-Frank Section 1502. Join us as PwC panelists from our Health Industries practice lead a discussion addressing the rule, what life sciences products are likely to be covered, and what companies should be doing now.
What will the impact of the US presidential election be on the cost of providing healthcare for your business? In our latest report, PwC's Health Research Institute provides a roadmap of the many changes headed your way, and offers a roadmap on how to sidestep any obstacles implementation may toss your way
What are the recent investment trends and opportunities in global healthcare markets and what regions are likely to draw future merger and acquisition activity? Our 2Q 2012 edition focuses on the rapid pace of M&A activity in the key healthcare M&A emerging markets of Brazil and China.
What are the recent investment trends and opportunities in global healthcare markets and what regions are likely to draw future merger and acquisition activity? Our 1Q 2012 edition focuses on investments in the evolving global hospital sector. Global deals activity has gotten off to a slow start in 2012, with softer volumes and smaller deal sizes reflecting continued economic uncertainty in global markets.
The Supreme Court heard arguments concerning the Affordable Care Act in March 2012 and expects to issue its decision on the constitutionality of the Affordable Care Act by the end of June 2012. If the law should be invalidated by the Supreme Court, either in whole or in part, there could be significant accounting and financial reporting implications. This PwC Pharmaceutical and Life Sciences Industry Alert focuses on the potential accounting implications of the Supreme Court decision on the Affordable Care Act.
Healthcare spending in the United States is expected to grow at a historically low rate of 7.5 percent next year, according to the annual Behind the numbers report on medical cost trend, published by PwC Health Research Institute. More than half of the employers surveyed are considering increasing employees' share of health benefit cost and expanding health and wellness programs in 2013.
In February 2012, the Greek government announced a debt restructuring which required holders to exchange their two-year and three-year bonds, currently scheduled to mature in December 2012 and 2013, for new non-interest bearing government bonds with longer maturities and a reduced redemption value. This edition of PwC's Pharmaceutical and Life Sciences Industry Alert discusses why pharmaceutical companies will need to evaluate the debt restructuring in order to properly assess the accounting impact of this event.
With one half of health industry executives saying they are concerned about how to integrate social media data into their business strategy there is a recognition social media presents a significant industry challenge.
The Departments of Treasury, Labor and Health and Human Services have released final rules regarding the summary of benefits and coverage required to be provided by health insurance issuers and group health plans under the Patient Protection and Affordable Care Act ("PPACA"). For more, read this edition of HRS insight.
There continues to be significant economic problems in some European countries that are members of the single currency (the Euro zone) as well as potential uncertainty about the single currency itself. This Pharma and Life Sciences Alert discusses why austerity programs aimed at reducing debt levels in these countries have not eliminated the possibility that some European countries could default on sovereign debt and other governmental obligations.
The FASB and IASB released an updated exposure draft, Revenue from Contract with Customers, on November 14, 2011, and are requesting comments by March 13, 2012. In Dataline 2011-35, we share our analysis of and insight on the overall proposal. This industry supplement to Dataline 2011-35 provides specific examples and assessments of the potential affect of the updated proposal on the pharmaceutical and life sciences industry.